PWM
REGN icon

Pinnacle Wealth Management’s Regeneron Pharmaceuticals REGN Stock Holding History

Pinnacle Wealth Management’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-2,559
Closed -$1.76M – 57
2022
Q3 		$1.76M Buy
+2,559
New +$1.61M 2.14% 13

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Pinnacle Wealth Management's REGN Position: Q4 2022 in Review

Pinnacle Wealth Management sold out of Regeneron Pharmaceuticals (REGN) in Q4 2022, closing a stake of 2,559 shares — an estimated $1.76M sold.

Pinnacle Wealth Management first reported a position in REGN in Q3 2022 and held it in 1 quarter. The position peaked at $1.76M in Q3 2022. 1,159 funds tracked by Wall St. Rank hold REGN as of Q4 2022.

  • Pinnacle Wealth Management reported no remaining Regeneron Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Pinnacle Wealth Management sold 2,559 Regeneron Pharmaceuticals shares in Q4 2022, an estimated $1.76M.
  • Pinnacle Wealth Management first reported a position in Regeneron Pharmaceuticals in Q3 2022 and held it in 1 quarter.
  • Pinnacle Wealth Management's Regeneron Pharmaceuticals position peaked at $1.76M in Q3 2022.
  • 1,159 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q4 2022.

Based on Pinnacle Wealth Management's 13F filing for Q4 2022, filed 30 Jan 2023.